Evolution of the Average Target: Cognition Therapeutics, Inc.

Evolution of the Target Price: Cognition Therapeutics, Inc.

Changes in Analyst Recommendations: Cognition Therapeutics, Inc.

d7944c9640527f0af33fe66f7a72.O-uT1gQ2WGDx7khZ6yxujtPbxj6Z3VrT6WY3b2MrmOQ.Q4nRpktbDjOnvC8cs2hWw5zriFzTjSyVuxNbGChd0dJ6vvy-UHhhDpmJOw~b317ced1d53a05daab90bcfa84ec122a
11-21 B. Riley Raises Price Target on Cognition Therapeutics to $3 From $2, Keeps Buy Rating MT
25-08-07 Cognition Therapeutics Q2 net loss narrows to $6.7 mln RE
25-02-06 B. Riley Adjusts Cognition Therapeutics Price Target to $2 From $1.50, Maintains Buy Rating MT
24-12-19 B. Riley Upgrades Cognition Therapeutics to Buy From Neutral, Lifts PT to $1.50 From $1 MT
24-08-06 B. Riley Downgrades Cognition Therapeutics to Neutral From Buy, $1 Price Target MT
24-07-30 Cantor Fitzgerald Downgrades Cognition Therapeutics to Neutral From Overweight MT
24-06-07 Chardan Research Initiates Cognition Therapeutics With Buy Rating, $11 Price Target MT
24-05-29 HC Wainwright Starts Cognition Therapeutics With Buy Rating, $10 Price Target MT
23-08-14 Ladenburg Thalmann Cuts Cognition Therapeutics' Price Target to $6 From $10, Keeps Buy Rating MT
23-04-06 B. Riley Cuts Cognition Therapeutics' PT to $5 From $15, Notes Near-Term Dilution, Expanding R&D Efforts to Execute on Phase II/III Programs; Keeps Buy Rating MT
22-11-15 Oppenheimer Adjusts Cognition Therapeutics Price Target to $9 From $18, Maintains Outperform Rating MT
22-09-29 Cantor Fitzgerald Starts Cognition Therapeutics at Overweight With $12 Price Target MT
22-04-22 Ladenburg Thalmann Starts Cognition Therapeutics at Buy With $10 Price Target MT
22-04-01 B. Riley Lowers Cognition Therapeutics' PT to $15 from $20, Keeps Buy Rating MT
22-03-31 Oppenheimer Adjusts Cognition Therapeutics' Price Target to $18 From $22, Maintains Outperform Rating MT
22-01-24 B. Riley Lowers Cognition Therapeutics' Price Target to $20 from $27 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
21-11-03 Oppenheimer Starts Cognition Therapeutics at Outperform with $22 PT On Potential Offered By Lead Dementia Drug Candidate CT1812 MT
21-11-03 B. Riley Starts Cognition Therapeutics at Buy with $27 PT, Notes Conviction in Proprietary, Mid-Stage Pipeline MT
21-11-03 Oppenheimer Starts Cognition Therapeutics at Outperform with $22 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+220.51%
+16.92%
+17.91%
+15.47%
+66.29%
+23.62%
+8.57%
+15.96%
-8.01%
+62.99%
Average +44.02%
Weighted average by Cap. +22.76%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.040USD
Average target price
3.333USD
Spread / Average Target
+220.51%
High Price Target
4.000USD
Spread / Highest target
+284.62%
Low Price Target
3.000USD
Spread / Lowest Target
+188.46%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
  1. Stock Market
  2. Stocks
  3. CGTX Stock
  4. Consensus Cognition Therapeutics, Inc.
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!